Gonadotropin response to luteinizing hormone releasing hormone administration in secondary amenorrhea and galactorrhea syndromes.
Luteinizing hormone releasing hormone (LHRH), 100 mug, was administered to 60 patients with secondary amenorrhea. No side effects or adverse reactions occurred. Delayed FSH and LH peak outputs were observed in patients receiving LHRH subcutaneously rather than intravenously, but responses were otherwise comparable. The majority of patients with secondary amenorrhea had responses which fell into the 95% confidence limits of responses for normal ovulating women. Responses of patients with different forms of dysfunction may be similar, and patients with similar pathology may respond quite differently. The LHRH stimulation test may assist in the diagnosis of particular hypothalamic, pituitary, or gonadal dysfunction, but it must be used clinically in the context of a carefully integrated study.
D000238:Adenoma, Chromophobe / Q000150:complications; D000293:Adolescent; D000328:Adult; D000568:Amenorrhea / Q000097:blood* / Q000209:etiology; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D005687:Galactorrhea / Q000097:blood* / Q000209:etiology; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000009:adverse effects; D006065:Gonadotropins, Pituitary / Q000097:blood*; D006801:Humans; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D007775:Lactation Disorders / Q000097:blood*; D007986:Luteinizing Hormone / Q000097:blood; D010060:Ovulation; D010911:Pituitary Neoplasms / Q000150:complications*; D011085:Polycystic Ovary Syndrome / Q000150:complications; D011247:Pregnancy; D011602:Psychophysiologic Disorders
D006065:Gonadotropins, Pituitary; D007987:Gonadotropin-Releasing Hormone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone